Clinical Trials Browser

Leukemia, Lymphoid × venetoclax × 1 year × Clear all

NCT03708003 2025-12-30

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell